Benlysta Lowers Disease Activity and Eases Fatigue in SLE Patients over Long Term, Trial Finds

Prolonged treatment with Benlysta (belimumab) offers safe and effective control of disease activity, improves life quality and eases fatigue in patients with active, autoantibody-positive systemic lupus erythematosus (SLE), according to seven-year clinical trial results released by GSK, the drug’s developer. These findings come from a continuation study of patients who completed the Phase…

Lupus Patients on Baseline Steroids Combined with Benlysta May Improve

Results from two Phase 3 trials revealed that patients with systemic lupus erythematosus (SLE) can benefit from the recombinant human monoclonal antibody Benlysta (belimumab) when it is used with steroids. The study, “Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus,”…